The 3 Biggest Myths About Tax Inversion Deals
With U.S. pharmaceutical giant Pfizer rolling out the largest-ever inversion play, the buzz surrounding the tax-motivated deal structure is reaching new heights, but that doesn't mean all the information buzzing around...To view the full article, register now.
Already a subscriber? Click here to view full article